ES2647360T5 - Célula madre pluripotente que puede aislarse de tejido corporal - Google Patents

Célula madre pluripotente que puede aislarse de tejido corporal Download PDF

Info

Publication number
ES2647360T5
ES2647360T5 ES10799956T ES10799956T ES2647360T5 ES 2647360 T5 ES2647360 T5 ES 2647360T5 ES 10799956 T ES10799956 T ES 10799956T ES 10799956 T ES10799956 T ES 10799956T ES 2647360 T5 ES2647360 T5 ES 2647360T5
Authority
ES
Spain
Prior art keywords
cells
cell
pluripotent stem
muse
fractions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10799956T
Other languages
English (en)
Spanish (es)
Other versions
ES2647360T3 (es
Inventor
Mari Dezawa
Yoshinori Fujiyoshi
Youichi Nabeshima
Shohei Wakao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2647360(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2647360T3 publication Critical patent/ES2647360T3/es
Publication of ES2647360T5 publication Critical patent/ES2647360T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
ES10799956T 2009-07-15 2010-07-15 Célula madre pluripotente que puede aislarse de tejido corporal Active ES2647360T5 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21378809P 2009-07-15 2009-07-15
US213788P 2009-07-15
US29015909P 2009-12-24 2009-12-24
US290159P 2009-12-24
PCT/JP2010/062480 WO2011007900A1 (ja) 2009-07-15 2010-07-15 生体組織から単離できる多能性幹細胞

Publications (2)

Publication Number Publication Date
ES2647360T3 ES2647360T3 (es) 2017-12-21
ES2647360T5 true ES2647360T5 (es) 2021-06-14

Family

ID=43449509

Family Applications (3)

Application Number Title Priority Date Filing Date
ES17163323T Active ES2831030T3 (es) 2009-07-15 2010-07-15 Célula madre pluripotente que puede aislarse de tejido corporal
ES20160074T Active ES3015175T3 (en) 2009-07-15 2010-07-15 Pluripotent stem cell that can be isolated from body tissue
ES10799956T Active ES2647360T5 (es) 2009-07-15 2010-07-15 Célula madre pluripotente que puede aislarse de tejido corporal

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES17163323T Active ES2831030T3 (es) 2009-07-15 2010-07-15 Célula madre pluripotente que puede aislarse de tejido corporal
ES20160074T Active ES3015175T3 (en) 2009-07-15 2010-07-15 Pluripotent stem cell that can be isolated from body tissue

Country Status (16)

Country Link
US (1) US9550975B2 (OSRAM)
EP (3) EP3214170B1 (OSRAM)
JP (7) JP5185443B2 (OSRAM)
KR (4) KR20120069663A (OSRAM)
CN (2) CN107012117B (OSRAM)
AU (1) AU2010271722B8 (OSRAM)
CA (1) CA2768238C (OSRAM)
DK (2) DK3214170T3 (OSRAM)
ES (3) ES2831030T3 (OSRAM)
HR (1) HRP20250245T1 (OSRAM)
HU (3) HUE052559T2 (OSRAM)
NO (1) NO2455452T3 (OSRAM)
PL (3) PL3680323T3 (OSRAM)
PT (2) PT2455452T (OSRAM)
SG (1) SG177705A1 (OSRAM)
WO (1) WO2011007900A1 (OSRAM)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014132830A (ja) * 2011-03-30 2014-07-24 Clio Inc 生体の臍帯又は脂肪組織から単離できる多能性幹細胞
JP2014133703A (ja) * 2011-03-30 2014-07-24 Clio Inc 生体組織から単離できるｓｓｅａ−３陽性の多能性幹細胞を含む他家移植用細胞治療用組成物
US9399758B2 (en) 2009-07-15 2016-07-26 Mari Dezawa SSEA3(+) pluripotent stem cell that can be isolated from body tissue
US9550975B2 (en) * 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
US8883430B2 (en) 2009-08-21 2014-11-11 The Board Of Trustees Of The Leland Stanford Junior University Enhanced efficiency of induced pluripotent stem cell generation from human somatic cells
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
SG10201914092XA (en) * 2011-06-06 2020-03-30 ReGenesys BVBA Expansion of stem cells in hollow fiber bioreactors
EP2737057B1 (en) 2011-07-27 2018-10-24 Kyoto University Novel markers for dopaminergic neuron progenitor cells
KR101751355B1 (ko) 2011-08-24 2017-07-04 (주)아모레퍼시픽 인간 피부 진피 유래 성체 줄기세포
WO2013058403A1 (ja) 2011-10-21 2013-04-25 国立大学法人京都大学 層流による多能性維持単一分散細胞培養法
CN104284976A (zh) * 2012-03-06 2015-01-14 Sct&B公司 胎盘干细胞及其分离方法与应用
KR20150045935A (ko) * 2012-04-24 2015-04-29 더 브리검 앤드 우먼즈 하스피털, 인크. 다능성 세포를 다시 생성하는 방법
US20140030244A1 (en) * 2012-07-27 2014-01-30 Bioquark, Inc. Extracts isolated from electroporated ambhibian oocytes and use thereof in treating diseases and disorders
WO2014027474A1 (ja) 2012-08-17 2014-02-20 株式会社Ｃｌｉｏ 心筋梗塞の修復再生を誘導する多能性幹細胞
US20150329827A1 (en) * 2012-12-21 2015-11-19 Rutgers , The State University Of New Jersey Muse cells isolation and expansion
US9709554B2 (en) 2013-01-31 2017-07-18 Rutgers, The State University Of New Jersey In vitro model of macrosteatotic (fatty) liver
JP6495658B2 (ja) 2013-02-08 2019-04-03 国立大学法人京都大学 巨核球及び血小板の製造方法
WO2014133090A1 (ja) * 2013-02-28 2014-09-04 国立大学法人浜松医科大学 脳腫瘍治療のための多能性幹細胞
JP6511606B2 (ja) 2013-03-01 2019-05-15 株式会社生命科学インスティテュート 多能性幹細胞を損傷部位に誘導する遊走因子を含む医薬組成物
TW201522637A (zh) * 2013-03-15 2015-06-16 Jackson Lab 非胚胎幹細胞之單離及其用途
JP6473077B2 (ja) 2013-03-21 2019-02-20 国立大学法人京都大学 神経分化誘導用の多能性幹細胞
WO2014157257A1 (ja) 2013-03-25 2014-10-02 公益財団法人先端医療振興財団 細胞の選別方法
EP2985344B1 (en) 2013-04-12 2018-07-18 Kyoto University Method for inducing alveolar epithelium progenitor cells
EP2998391B1 (en) 2013-05-14 2020-02-19 Kyoto University Efficient myocardial cell induction method
JP2016519939A (ja) 2013-05-22 2016-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 多能性ヒト脂肪成体幹細胞：単離、キャラクタリゼーションおよび臨床的意味
MX2016001247A (es) 2013-07-30 2016-08-17 Musculoskeletal Transplant Foundation Matrices derivadas de tejido suave acelular y metodos para preparar las mismas.
EP3031905A4 (en) 2013-08-07 2017-04-26 Kyoto University Method for producing pancreatic hormone-producing cell
US10265347B2 (en) 2013-08-29 2019-04-23 Norimasa Miura Biomolecular group related to cell anti-aging
JP6353452B2 (ja) * 2013-09-04 2018-07-04 株式会社大塚製薬工場 多能性幹細胞の調製方法
MY184219A (en) 2013-09-05 2021-03-26 Univ Kyoto New method for inducing dopamine-producing neural precursor cells
WO2015064754A1 (ja) 2013-11-01 2015-05-07 国立大学法人京都大学 新規軟骨細胞誘導方法
US9987310B2 (en) 2013-11-27 2018-06-05 University Of Louisville Research Foundation, Inc. Cardiac progenitor cells and methods of use therefor
JP6519038B2 (ja) * 2014-02-26 2019-05-29 株式会社生命科学インスティテュート 脳梗塞治療のための多能性幹細胞
JP2015160820A (ja) * 2014-02-26 2015-09-07 株式会社Ｃｌｉｏ 慢性腎障害治療のための多能性幹細胞
IL247890B2 (en) 2014-03-19 2024-08-01 Vcell Therapeutics Inc Methods related to stem cells
WO2015178431A1 (ja) 2014-05-21 2015-11-26 国立大学法人京都大学 膵芽細胞の製造方法および膵芽細胞を含む膵疾患治療剤
KR101592401B1 (ko) * 2014-06-13 2016-02-05 주식회사 비비에이치씨 지방-유래 중간엽 줄기세포로부터 유도만능 줄기세포를 제조하는 방법 및 그 방법에 의해 제조된 유도만능 줄기세포
JP6391364B2 (ja) * 2014-08-25 2018-09-19 国立大学法人 鹿児島大学 認知機能障害改善用細胞製剤
JP6452107B2 (ja) * 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞
KR101700598B1 (ko) * 2014-11-11 2017-01-31 한국원자력의학원 Cd105를 포함하는 줄기세포능을 가진 섬유아세포 분리용 바이오마커 조성물 및 이를 이용한 줄기세포능을 가진 섬유아세포 분리 방법
US10531957B2 (en) 2015-05-21 2020-01-14 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
KR20180108903A (ko) * 2015-05-29 2018-10-04 니폰 조키 세야쿠 가부시키가이샤 다능성 간세포 유주 촉진제
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
JP6627027B2 (ja) * 2015-09-11 2020-01-08 福美人株式会社 皮膚細胞の活性化作用を呈するフラボノイド誘導体
AU2017207154B2 (en) * 2016-01-15 2020-09-17 Mari Dezawa Mobilization of pluripotent stem cells for ischemic cerebral infarction
JP6770673B2 (ja) * 2016-02-26 2020-10-21 国立大学法人東海国立大学機構 急性心筋梗塞の予後マーカー及びその利用
BR112018068820B1 (pt) 2016-03-17 2022-11-16 Synova Life Sciences, Inc Método para isolar células-tronco do tecido adiposo e dispositivo para realizar o dito método
WO2017183736A1 (ja) 2016-04-22 2017-10-26 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
KR20200127039A (ko) 2016-05-16 2020-11-09 고쿠리츠 다이가쿠 호우징 도우카이 고쿠리츠 다이가쿠 기코우 다능성 간세포에 의한 주산기 뇌장애의 개선 및 치료
US20190201455A1 (en) 2016-07-01 2019-07-04 Tohoku University Prophylactic or therapeutic agent for organ fibrosis
JP7029729B2 (ja) 2016-07-29 2022-03-04 国立大学法人東北大学 血管障害の予防又は治療剤
WO2018025973A1 (ja) 2016-08-03 2018-02-08 国立大学法人名古屋大学 多能性幹細胞による慢性肺疾患の改善及び治療
US11920180B2 (en) 2016-08-03 2024-03-05 Tohoku University Method for inducing differentiation of pluripotent stem cells in vitro
SG10202101160RA (en) 2016-08-03 2021-03-30 Hiroshi Yabuki Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
US20200270579A1 (en) 2017-02-03 2020-08-27 Kyushu University, National University Corporation Method for preparing dental pulp stem cells from cells derived from dental pulp tissue
CA3058306A1 (en) * 2017-03-28 2018-10-04 Ajinomoto Co., Inc. Additive for undifferentiation maintaining medium
EP3643316A4 (en) * 2017-06-19 2021-01-20 National University Corporation Hokkaido University TREATMENT PRODUCTS FOR EPIDERMOLYSIS BULLOSA
SG11201912831TA (en) 2017-06-20 2020-01-30 Univ Nagoya Nat Univ Corp Amelioration and treatment of brain disorder resulting from fetal growth retardation using pluripotent stem cells
SG11202003507QA (en) 2017-10-17 2020-05-28 Univ Hiroshima Pluripotent stem cells inducing osteochondral repair
AU2018364852B2 (en) * 2017-11-10 2022-06-30 Regenesis Science Co., Ltd. Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease
JP7336143B2 (ja) 2017-11-28 2023-08-31 セルツーイン、 インコーポレイテッド リアルタイムなグルタチオンの測定による治療用細胞の品質向上方法
JP6604492B2 (ja) * 2018-04-09 2019-11-13 株式会社生命科学インスティテュート 脳梗塞治療のための多能性幹細胞
AU2019268009A1 (en) 2018-05-09 2021-01-07 Life Science Institute, Inc. Therapeutic agent for spinal cord injury
JP7072777B2 (ja) * 2018-07-03 2022-05-23 株式会社生命科学インスティテュート 慢性腎障害治療のための多能性幹細胞
US20210299331A1 (en) 2018-07-19 2021-09-30 Kyoto University Pluripotent stem cell-derived plate-shaped cartilage and method for producing the same
JP7369346B2 (ja) * 2018-11-14 2023-10-26 株式会社片岡製作所 インスリン産生細胞の製造方法、及び組成物
JP7473207B2 (ja) * 2018-11-30 2024-04-23 京都府公立大学法人 末梢血流障害の治療剤
WO2020130147A1 (ja) 2018-12-21 2020-06-25 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
EP3952891A4 (en) * 2019-04-09 2023-01-25 Rutgers, the State University of New Jersey Methods for enriching populations of cells
EP4011382A1 (en) 2019-08-09 2022-06-15 Tohoku University Agent for treating or preventing cerebrovascular dementia
JP7627496B2 (ja) * 2019-09-05 2025-02-06 国立大学法人東北大学 心筋炎の治療剤
EP4043553A4 (en) 2019-10-01 2023-11-22 Kyoto University METHOD FOR ISOLATING URETERIC BUD TIP CELLS
EP4052718A1 (en) * 2019-10-31 2022-09-07 Life Science Institute, Inc. Therapy for interstitial cystitis by pluripotent stem cells
US20230030814A1 (en) 2019-12-12 2023-02-02 National University Corporation Chiba University Freeze-Dried Preparations Comprising Megakaryocytes and Platelets
US20230212519A1 (en) 2020-03-19 2023-07-06 Orizuru Therapeutics, Inc. Method for purifying cardiomyocytes
US20230136878A1 (en) 2020-03-19 2023-05-04 Orizuru Therapeutics, Inc. Cardiomyocyte purification method
JPWO2021201286A1 (OSRAM) 2020-04-02 2021-10-07
EP4180516A4 (en) 2020-07-13 2024-01-17 Kyoto University SKELETON MUSCLE PRECURSOR CELLS AND METHOD FOR PURIFICATION THEREOF, COMPOSITION FOR THE TREATMENT OF MYOGENIC DISEASES AND METHOD FOR PRODUCING SKELETON MUSCLE PRECURSOR CELLS CONTAINING CELL GROUPS
US20230270790A1 (en) * 2020-07-15 2023-08-31 National University Corporation Okayama University Pluripotent stem cells effective for treatment of motor neuron disease (mnd)
JP2021073305A (ja) * 2021-02-09 2021-05-13 株式会社生命科学インスティテュート 慢性腎障害治療のための多能性幹細胞
TWI832070B (zh) * 2021-07-15 2024-02-11 國璽幹細胞應用技術股份有限公司 幹細胞製劑用於治療關節炎的用途及用於製備幹細胞製劑的方法
JP2023041486A (ja) * 2021-09-13 2023-03-24 国立大学法人東北大学 毛髪損傷の治療剤
WO2023153464A1 (ja) 2022-02-09 2023-08-17 住友ファーマ株式会社 多能性幹細胞から中脳底板領域の神経系細胞への分化における、培養液中の細胞の分化能を判定する方法
WO2023228908A1 (ja) 2022-05-23 2023-11-30 国立大学法人京都大学 腎集合管細胞および腎盂上皮細胞の製造方法
TW202444899A (zh) 2023-04-03 2024-11-16 日商大塚製藥股份有限公司 巨核細胞之製造方法
WO2024248017A1 (ja) 2023-05-29 2024-12-05 国立研究開発法人理化学研究所 心筋細胞を成熟させる方法及び成熟した心筋細胞の製造方法
CN117187174B (zh) * 2023-11-08 2024-02-06 广州正源生物技术有限公司 一种Muse细胞培养基以及一种脂肪Muse细胞的提取方法
JP2025123077A (ja) * 2024-02-09 2025-08-22 国立大学法人東北大学 脊髄梗塞治療のための多能性幹細胞

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5398941B2 (ja) 1999-08-05 2014-01-29 エイビーティー ホールディング カンパニー 多能性成体幹細胞およびそれを単離する方法
US7575921B2 (en) * 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US20020151050A1 (en) * 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
JP4182742B2 (ja) 2002-12-12 2008-11-19 日産自動車株式会社 自動車の前部車体構造
WO2005017117A2 (en) 2003-08-14 2005-02-24 Martin Haas Multipotent amniotic fetal stem cells (mafsc) and banking of same
CA2536909A1 (en) * 2003-08-29 2005-03-10 Regents Of The University Of Minnesota Kidney derived stem cells and methods for their isolation, differentiation and use
US20060216821A1 (en) * 2004-02-26 2006-09-28 Reliance Life Sciences Pvt. Ltd. Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof
AU2006281032B2 (en) * 2005-05-17 2010-09-02 Reliance Life Sciences Pvt Ltd Establishment of a human embryonic stem cell line using mammalian cells
US9388382B2 (en) * 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
AU2006304390A1 (en) 2005-10-17 2007-04-26 Academia Sinica Pulmonary stem cells, related methods and kits
EP4223769A3 (en) 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor
WO2008080200A1 (en) 2006-12-29 2008-07-10 Irina Kerkis Process for obtaining stem cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP2214497A4 (en) * 2007-10-30 2010-11-24 Univ Louisville Res Found USES AND ISOLATION OF VERY SMALL EMBRYONIC TYPE STEM CELLS (VSEL)
US20090172832A1 (en) * 2007-12-28 2009-07-02 Timothy Caspar Expression of rubisco enzyme from a non-rubisco locus
ITRM20080342A1 (it) * 2008-06-26 2009-12-27 Univ Degli Studi Udine Cellule di polpa dentale midollo-simili, metodi per isolamento ed uso.
US9550975B2 (en) * 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue

Also Published As

Publication number Publication date
AU2010271722A1 (en) 2012-03-01
EP3680323C0 (en) 2024-11-27
PL2455452T3 (pl) 2018-02-28
EP2455452B2 (en) 2020-10-07
KR20150063168A (ko) 2015-06-08
PL3214170T3 (pl) 2021-04-06
EP2455452A1 (en) 2012-05-23
JP2017122095A (ja) 2017-07-13
EP3680323B1 (en) 2024-11-27
PL2455452T5 (pl) 2021-01-25
CN102858951B (zh) 2016-12-07
EP3214170B1 (en) 2020-09-02
EP2455452B1 (en) 2017-09-06
ES2831030T3 (es) 2021-06-07
JP2021184754A (ja) 2021-12-09
NO2455452T3 (OSRAM) 2018-02-03
JP6092357B2 (ja) 2017-03-08
DK3214170T3 (da) 2020-10-12
JP2020058385A (ja) 2020-04-16
KR20170089959A (ko) 2017-08-04
EP3680323A1 (en) 2020-07-15
KR101764080B1 (ko) 2017-08-01
HUE037448T2 (hu) 2018-09-28
WO2011007900A1 (ja) 2011-01-20
HRP20250245T1 (hr) 2025-06-20
KR101945343B1 (ko) 2019-02-07
KR20160040728A (ko) 2016-04-14
JP6641441B2 (ja) 2020-02-05
JP2012139246A (ja) 2012-07-26
CN107012117A (zh) 2017-08-04
JP6416298B2 (ja) 2018-10-31
US9550975B2 (en) 2017-01-24
JP7134317B2 (ja) 2022-09-09
AU2010271722B8 (en) 2014-07-03
JP2016028614A (ja) 2016-03-03
KR101651795B1 (ko) 2016-08-26
PT2455452T (pt) 2017-11-20
ES3015175T3 (en) 2025-04-29
PT3214170T (pt) 2020-11-16
AU2010271722B2 (en) 2014-05-29
CA2768238C (en) 2017-11-28
CN102858951A (zh) 2013-01-02
HUE071170T2 (hu) 2025-08-28
JP5852503B2 (ja) 2016-02-03
CN107012117B (zh) 2020-10-23
JPWO2011007900A1 (ja) 2012-12-27
JP6937821B2 (ja) 2021-09-22
EP2455452A4 (en) 2013-11-27
ES2647360T3 (es) 2017-12-21
DK2455452T4 (da) 2020-11-02
US20110070647A1 (en) 2011-03-24
CA2768238A1 (en) 2011-01-20
EP3214170A1 (en) 2017-09-06
PL3680323T3 (pl) 2025-09-01
JP5185443B2 (ja) 2013-04-17
DK2455452T3 (en) 2017-10-23
SG177705A1 (en) 2012-02-28
JP2018203780A (ja) 2018-12-27
KR20120069663A (ko) 2012-06-28
HUE052559T2 (hu) 2021-05-28

Similar Documents

Publication Publication Date Title
ES2647360T5 (es) Célula madre pluripotente que puede aislarse de tejido corporal
US11261426B2 (en) Pluripotent stem cell that can be isolated from body tissue